Álvaro Reyes

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction

Shigeto Ishidoya, Jeremiah J. Morrissey, Ruth McCracken et al. · Kidney International · 1995 · 327 citations · Full text

Medicine, Nephrology, Urology +13

Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data

Marjan Walli-Attaei, Rasha Khatib, Martin McKee et al. · The Lancet Public Health · 2017 · 214 citations · Full text

Pharmacy, Pharmacoeconomics, Preventive Medicine +15

Enalapril reduces collagen type IV synthesis and expansion of the interstitium in the obstructed rat kidney

Hiroyuki Kaneto, Jeremiah J. Morrissey, Ruth McCracken et al. · Kidney International · 1994 · 210 citations · Full text

Pharmacy, Nephrology, Pharmacotherapy +12